These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19385504)

  • 1. Endocannabinoid system and cardio-metabolic risk.
    Loh KY; Kew ST
    Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
    Deedwania P
    Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
    Bramlage P; Böcking W; Kirch W
    Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
    Sulcová A
    Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
    Kyrou I; Valsamakis G; Tsigos C
    Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid system: a new approach to control cardiovascular disease.
    Cannon CP
    Clin Cornerstone; 2005; 7(2-3):17-26. PubMed ID: 16473257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
    Woods SC
    JAAPA; 2007 Nov; Suppl Endocannabinoid():7-10. PubMed ID: 18047036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the endocannabinoid system in metabolic control.
    Wang J; Ueda N
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):1-10. PubMed ID: 18090663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing cardiometabolic risk through selective antagonism of CB1 receptors.
    Van Gaal L
    Clin Cornerstone; 2007; 8 Suppl 6():S24-9. PubMed ID: 17948364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
    Horvath TL
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S30-2. PubMed ID: 16570102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system and the control of glucose homeostasis.
    Nogueiras R; Rohner-Jeanrenaud F; Woods SC; Tschöp MH
    J Neuroendocrinol; 2008 May; 20 Suppl 1():147-51. PubMed ID: 18426514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocannabinoid system: a promising target for the management of type 2 diabetes.
    Scheen AJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.